Nasdaq Opt News Today

Opthea (NASDAQ:OPT – Get Free Report) and Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends. Volatility & Risk Opthea has a beta of […]

Opthea (NASDAQ:OPT – Free Report) had its price target decreased by Oppenheimer from $31.00 to $16.00 in a report issued on Wednesday, MarketBeat reports. Oppenheimer currently has an outperform rating on the stock. Separately, HC Wainwright reiterated a buy rating and set a $14.00 target price on shares of Opthea in a research report on […]

HC Wainwright restated their buy rating on shares of Opthea (NASDAQ:OPT – Free Report) in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has a $14.00 target price on the stock. Separately, EF Hutton Acquisition Co. I started coverage on Opthea in a report on Monday, April 17th. They set a […]

Opthea (NASDAQ:OPT – Free Report) and Angion Biomedica (NASDAQ:ANGN – Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Valuation & Earnings This table compares Opthea and Angion Biomedica’s […]

Opthea (NASDAQ:OPT – Get Rating) and Protalix BioTherapeutics (NYSE:PLX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation. Earnings & Valuation This table compares Opthea and Protalix BioTherapeutics’ […]

Opthea (NASDAQ:OPT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday, Zacks.com reports. According to Zacks, “Opthea Limited is a biotechnology company. It develops and commercializes therapies primarily for eye disease principally in Australia. Opthea Limited […]

Opthea Limited (NASDAQ:OPT – Get Rating) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 52,900 shares, a growth of 41.8% from the March 15th total of 37,300 shares. Based on an average trading volume of 5,600 shares, the short-interest ratio is currently […]

Opthea (NASDAQ:OPT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Opthea Limited is a biotechnology company. It develops and commercializes therapies primarily for eye disease principally in Australia. Opthea Limited is based […]

Zacks Investment Research upgraded shares of Opthea (NASDAQ:OPT – Get Rating) from a sell rating to a hold rating in a report published on Thursday, Zacks.com reports. According to Zacks, “Opthea Limited is a biotechnology company. It develops and commercializes therapies primarily for eye disease principally in Australia. Opthea Limited is based in South Yarra, […]

Opthea Limited (NASDAQ:OPT – Get Rating) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 45,500 shares, a decrease of 38.4% from the January 31st total of 73,900 shares. Based on an average trading volume of 6,500 shares, the short-interest […]